On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months.

The initiative comprises two parallel tranches:

1. H-Share Incentive Scheme Purchase • Up to RMB100.00 million of internal funds will be provided to an independent trustee to buy existing H-shares on-market for future awards under the company’s H-Share Incentive Scheme. • Any share grants funded by these purchases will follow Rule 17.12 of the Hong Kong Listing Rules.

2. General Mandate Share Repurchase • Separately, up to RMB100.00 million will be used under the general mandate approved at the 5 June 2026 AGM to repurchase H-shares in the open market. • Repurchased shares will be held as treasury stock.

Management highlighted that the dual programme signals confidence in the group’s business outlook while maintaining a solid financial position. The timing, volume and execution price of each transaction remain subject to market conditions and board discretion.

The company confirmed that all activities will adhere to its Articles of Association, the Hong Kong Listing Rules and other applicable regulations. Shareholders and potential investors were advised to exercise caution when trading the company’s securities, given that actual purchase and repurchase volumes are not assured.